Infinity taps CRO Pharm-Olam for a Phase II lymphoma study

Houston CRO Pharm-Olam is on board to help Infinity Pharmaceuticals ($INFI) get its in-development lymphoma therapy through a Phase II trial, recruiting 230 patients in hopes of demonstrating an effect on survival.

The drug, duvelisib, is an inhibitor of the proteins PI3K-delta and PI3K-gamma, designed to interrupt the signaling process that allows malignant B-cells to proliferate. Infinity, partnered with AbbVie ($ABBV), is working through 7 clinical trials in an attempt to establish duvelisib's efficacy in a range of hematological cancers.

The drug developer has now recruited Pharm-Olam to handle FRESCO, a Phase II study pitting duvelisib against chemotherapy in patients with relapsed or refractory follicular lymphoma who are already receiving Roche's ($RHHBY) Rituxan. The primary endpoint is a significant benefit in progression-free survival, and secondary goals include complete response rate, overall response, overall survival and duration of response.

Infinity previously tapped Pharm-Olam to handle data and project management for DYNAMO, a single-arm Phase II study testing duvelisib in non-Hodgkin lymphoma.

"In working with Pharm-Olam on the DYNAMO study, Pharm-Olam assigned Infinity a team of very capable individuals who complement one another in their unique strengths," Infinity Vice President Ross Pettit said in a statement. "We are pleased that they are now also supporting our Phase II FRESCO study."

AbbVie bought into duvelisib's potential in 2014, paying $275 million up front and promising $530 million more in exchange for commercial rights to the drug.

- read the statement
- get more on FRESCO

Suggested Articles

The platform uses wearables to continuously collect clinical data from study participants and applies machine learning to analyze the data.

WuXi AppTec has cut the ribbon on its expanded Laboratory Testing Division in New Jersey as it looks to boost its integrated testing service portfolio.

St. Jude, Microsoft and DNAnexus have created a data-sharing and analysis platform to help accelerate pediatric cancer research.